CAU
AXSM icon

Caxton Associates (UK)’s Axsome Therapeutics AXSM Stock Holding History

Caxton Associates (UK)’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$729K Buy
+4,311
New +$745K 0.02% 443
2025
Q2 		– Sell
-2,629
Closed -$307K – 699
2025
Q1 		$307K Buy
+2,629
New +$300K 0.01% 625

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caxton Associates (UK)'s AXSM Position: Q1 2026 in Review

Caxton Associates (UK) opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 4,311 shares worth $729K. The stake represents 0.02% of the portfolio and ranks #443 among its holdings. This is a return to the name: Caxton Associates (UK) previously reported a position in AXSM as recently as Q1 2025.

Caxton Associates (UK) first reported a position in AXSM in Q1 2025 and has held it in 2 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Caxton Associates (UK) held 4,311 shares of Axsome Therapeutics worth $729K as of Q1 2026.
  • Axsome Therapeutics was a new Caxton Associates (UK) position in Q1 2026.
  • Axsome Therapeutics made up 0.02% of Caxton Associates (UK)'s portfolio in Q1 2026, its #443 holding.
  • Caxton Associates (UK) first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.